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Treatment with a frontline BCR-ABL1 tyrosine kinase
inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib)
allows patients with chronic myeloid leukemia (CML) in
chronic phase (CP) to achieve a near normal life expectancy1, whereas treatment for CML in accelerated phase
(AP) is more problematic. While reports describe outcomes for patients with CML-AP at initial diagnosis2,3,
outcomes have been historically worse once CP disease
has progressed to AP. Approximately 50% of patients with
CML-AP who receive imatinib as initial treatment
develop imatinib resistance4 and experience disease progression5. Second-generation TKIs are indicated for
patients with CML-CP or advanced CML resistant to/
intolerant of prior therapy (including imatinib)6. After
initial approval of dasatinib twice a day (BID) for the
treatment of patients with CML resistant to/intolerant of
imatinib in all stages, this phase 3 CA180-035 study
(NCT00123487) was developed to investigate once (QD)
or twice (BID) a day dasatinib treatment in patients with
CML-AP, CML in blast phase, or Ph+ acute lymphoblastic leukemia resistant to/intolerant of imatinib.
Patients were randomized to receive dasatinib at either
70 mg BID (the standard dose at the time) or 140 mg QD.
Comparison of major hematologic response (MaHR)
between the dosage arms was the primary objective;
MaHR included either a complete hematologic response
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(CHR) or no evidence of leukemia. Data from the 1-year
and 2-year study reports (patients with 6.5 and 15 months’
median follow-up, respectively) noted that patients with
CML-AP in the QD or BID arms obtained similar MaHR
and major cytogenetic responses4,7. Patients who did not
progress, die, or withdraw consent were followed for at
least 7 years from the study start. Following the primary
analysis after 2 years of the study, long-term safety outcomes in patients with clinical beneﬁt who remained on
study became the primary objective. Subsequently, efﬁcacy, as deﬁned by MaHR, was assessed 5 years after the
study start, and safety data and date/cause of death were
collected out to 7 years. The majority of the patients who
remained on study at 2 years were in the CML-AP cohort
(110/128; [86%]). Long-term efﬁcacy and safety data,
beyond 2 years, had not previously been reported in these
patients with CML-AP, warranting additional follow-up.
As previously described, patients were diagnosed with
CML-AP based on the standard deﬁnition (i.e., hematologic criteria4 or clonal evolution); patients with progression of a prior CML-AP diagnosis after achieving a
hematologic response were also eligible4. Clonal evolution
included additional chromosomal abnormalities besides
the Ph chromosome (e.g., +8, +19, iso17q)8. After 2 years,
patients who experienced-speciﬁc AEs (e.g., any-grade
recurring ﬂuid retention, including pleural and/or pericardial effusion, or any-grade gastrointestinal bleed
despite dose reduction by one level) were allowed to
switch from BID to QD dosing, but data were analyzed
based on the initial randomization arm. After 2 years, 28
of 57 patients with CML-AP switched from BID to QD
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AP accelerated phase, BID twice a day, CI conﬁdence interval, CML chronic myeloid leukemia, NR not reported, OS overall survival, PFS progression-free survival, QD once a day
a
Duration of therapy for entire CML-AP population calculated at 5 years

30.3 (20.9–39.6)

57.6 (49.5–65.7)

20.7 (11.5–31.9) 21.3 (10.2–35.2) 42.1 (27.4–56.1) 41.5 (25.0–57.2) 31.1 (15.8–47.8) 24.0 (7.1–46.1)

32.8 (21.1–44.9) 45.6 (32.3–58.0) 52.6 (37.9–65.3) 67.9 (53.5–78.7) 54.3 (35.9–69.4) 60.2 (40.4–75.2) 45.0 (36.8–53.2)

PFS, % (95% CI)

NR
17.3 (1.6–81.7)
15.4 (0.2–91.4)
16.7 (0.3–83.7)
20.9 (0.5–92.9)
8.3 (0.5–85.4)
7.4 (<0.1–89.1)
Median duration of therapy excluding interruption, months

(range)

16.9 (0.12–93.2) 20.3 (1.6–83.8)
20.7 (0.4–84.6)
21.9 (0.5–92.9)
9.2 (0.5–86.1)
8.3 (0.0–90.1)
Median duration of therapy, months (range)

OS, % (95% CI)

30.5 (22.6–38.5)

NR

15.4 (0.00–67.0) 12.5a (0.4–66.3)

NR

a

NR
87 (21–206)
106 (34–174)
97 (22–171)
94 (20–162)
108 (13–178)
119 (26–216)
Average daily dose, mg (range)

BID (n = 160)
QD (n =1 57)
BID (n = 31)
QD (n = 34)
BID (n = 61)
BID (n = 64)

QD (n = 55)

CML-AP

QD (n = 67)

Prior AP diagnosis
Clonal evolution
Hematologic status

Table 1 Dosages and duration of therapy at 7 years and survival outcomes at 5 years based on CML-AP diagnosis

All patients diagnosed with
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dosing and 6 patients switched from QD to BID dosing
(Supplementary Table 1), limiting comparisons between
the dosage arms made after 2 years.
Of 611 randomized patients, 317 (52%) were diagnosed
with CML-AP at baseline and form the focus of this
report. Forty (13%) patients continued to receive the
treatment beyond 5 years. The most common reasons for
discontinuation were study-drug toxicity (QD: 29%; BID:
36%) or disease progression (QD: 27%; BID: 23%). The
median duration of dasatinib for patients with CML-AP
was 15 months (QD) or 13 months (BID) at the 5-year
cutoff (Table 1). At 7 years, the average daily dose of
dasatinib was similar for patients enrolled based on
hematologic criteria, clonal evolution, or prior diagnosis
of CML-AP (Table 1).
The rate of MaHR by 5 years (QD: 67%; BID: 69%) was
consistent with the 15-month report4, suggesting that
most patients may have reached maximum response by
15 months. The median duration of response in patients
with MaHR was 54 months at 5 years for the QD arm and
55 months for the BID arm (Fig. 1). Progression due to
loss of hematologic response slightly increased in both the
QD and BID dosage arms from 12% and 14%, respectively,
at 2 years to 15% in both arms at 5 years. The best
response of CHR at any time within 5 years was reached
in 51% and 54% of patients in the QD and BID arms,
respectively.
Dose schedule did not appear to affect 5-year rates of
progression-free survival (PFS) in patients with CML-AP
(Table 1 and Fig. 1). Patients with clonal evolution at
enrollment had a numerically higher 5-year PFS rate (42%
in both arms) compared to patients diagnosed based on
hematologic status (21% in both arms) or having a prior
diagnosis of CML-AP (QD: 31%; BID: 24%) (Table 1).
Five-year overall survival (OS) rates were numerically
higher in patients who were assigned BID versus QD
dosing (Fig. 1) whether diagnosis was based on hematologic status (46% vs. 33%), clonal evolution (68% vs. 53%),
or prior diagnosis of AP (60% vs. 54%) (Table 1). Although
5-year OS rates were higher for the BID versus QD arm,
the hazard ratio (HR; 1.37 [conﬁdence interval:
0.99–1.90]) suggests comparable effects.
After 7 years of follow-up, 83 of 157 (53%) and 67 of 160
(42%) patients had died in the QD and BID arms,
respectively, 25 (15%) and 17 (11%) within 30 days of their
last dasatinib dose. Only one patient died due to studydrug toxicity; the patient was enrolled into the QD arm
and died at <2 years on study.
Data relating to the presence or absence of mutations at
baseline and at the end of treatment/disease progression
were available for a total of 61 (QD) and 58 (BID) patients
at 5 years. The treatment arms had a similar proportion of
patients with no identiﬁed mutations at baseline (QD:
59% BID: 52%) and at the end of treatment (QD: 49%;
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Fig. 1 Efﬁcacy outcomes for patients with CML-AP by dosing
schedule. a Duration of MaHR for patients who achieved MaHR, b
PFS, and c OS are shown for the QD (solid lines) and BID (dashed lines)
dosing groups. Efﬁcacy analyses were conducted in the intention-totreat population of patients. BID twice a day, CI conﬁdence interval,
MaHR major hematologic response, NA not available, OS overall
survival, PFS progression-free survival, QD once a day

BID: 50%). Over the course of 5 years, 16 patients (QD: 10;
BID: 6) with no mutation at baseline had a new mutation
identiﬁed. The most common acquired mutations were
T315I (QD: 9; BID: 10) and F317L (QD: 5; BID: 4).
Conversely, of patients with an identiﬁed baseline mutation (QD: 25; BID: 28), the mutation was no longer
detected at 5 years in nine patients (QD: 4; BID: 5). The
Blood Cancer Journal
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most frequently lost mutations were E255K in the BID
arm (n = 5) and M351T in the QD arm (n = 4).
With respect to treatment-related AEs after 5 years of
follow-up (Supplementary Fig. 1), any-grade treatmentrelated ﬂuid retention events occurred more frequently in
the BID (53%) versus QD (40%) arm. Treatment-related
pleural effusion events of any grade slightly increased in
incidence between 2 years (QD: 31 [20%]; BID: 62 [39%])
and 5 years (QD: 43 [27%]; BID: 71 [44%]); grade 3–5
pleural effusion occurred in 14 (9%) and 15 (9%) patients in
the QD and BID arms, respectively, at 5 years. While the
incidence of pleural effusion was unchanged between 5 and
7 years in this study population, others have reported a
continuing risk over time after years of dasatinib treatment9.
At 5 years, there were four cases (two grade 3–5) of
drug-related congestive heart failure/cardiac dysfunction
in patients in the BID arm. Drug-related pulmonary
hypertension was diagnosed by echocardiogram in three
patients and indicated by X-ray in one case; it was
observed in one (grade 3–5) and three (grade 1–2)
patients in the QD and BID arms, respectively, within 5
years. The case in the QD arm was diagnosed on study
day 944 and the cases in the BID arm were diagnosed on
study days 36, 463, and 838. There were no cases of
pulmonary arterial hypertension (PAH); however, right
heart catheterization is required to conﬁrm PAH, and
only one procedure was performed.
The frequency of hematologic and biochemical AEs was
similar between the two dosage groups and was consistent
with the earlier study report4. No new safety signals were
identiﬁed in patients who remained on treatment after the
5-year cutoff.
Data from the CA180-035 trial represent the largest study
to date, with the longest follow-up, of dasatinib-treated
patients with CML-AP. After 5 years of treatment, rates of
MaHR, PFS, and OS in the QD and BID dosing arms
suggest comparable efﬁcacy with either regimen. Maintenance of MaHR suggests that some patients with CMLAP, who are responding well to second-line dasatinib
therapy and are at high risk for transplant-related mortality
may not need to seek a stem cell transplant. More AEs,
speciﬁcally ﬂuid-retention events (e.g., pleural effusion),
occurred in patients with CML-AP in the BID versus QD
arm. The reason for higher OS in the BID arm is unclear.
However, because there is no signiﬁcant difference in survival between these dosages, BID dosing has a more complicated safety proﬁle, and patients with CML-AP who
respond to and tolerate dasatinib treatment can maintain
long-term responses, the data reinforce the current QD
dose indication for treatment of patients with advanced
CML. Overall, the 5-year efﬁcacy and 7-year safety data in
dasatinib-treated patients after imatinib intolerance/resistance presented here support use of dasatinib for long-term
treatment of patients diagnosed with CML-AP.
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